Schall Law Firm Files Class Action Lawsuit Against Eiger BioPharmaceuticals
The Schall Law Firm, a national shareholder rights litigation firm based in Los Angeles, California, has announced the filing of a class action lawsuit against Eiger BioPharmaceuticals, Inc. The lawsuit alleges violations of ยงยง10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Eiger BioPharmaceuticals, Inc., a NASDAQ-listed company (EIGR), is at the center of this legal action. The lawsuit pertains to investors who purchased the company’s securities between March 10, 2021, and October 4, 2022, a period referred to as the “Class Period”.
Investors Encouraged to Contact Schall Law Firm
Investors who have incurred losses of $100,000 or more during the Class Period are being urged to contact the Schall Law Firm before the deadline of January 9, 2023. The firm specializes in shareholder rights litigation and has a track record of representing shareholders in protecting their rights.
Investors who fail to contact the firm before the deadline may forfeit their rights to participate in any potential recovery. The Schall Law Firm is encouraging investors to reach out to them to discuss their legal rights and options.
Implications for Investors
The lawsuit against Eiger BioPharmaceuticals could have significant implications for investors. If the allegations are proven true, investors who purchased securities during the Class Period may be entitled to compensation for their losses. This could potentially result in a significant financial recovery for those investors who have suffered substantial losses.
However, it’s important to note that this is a class action lawsuit, and the outcome is uncertain. Investors should carefully consider their options and seek legal advice before deciding to participate in the lawsuit.
Potential Risks and Upsides for Speculative Investors
For speculative investors, this situation presents both potential risks and upsides. On the one hand, the uncertainty surrounding the lawsuit could lead to increased volatility in Eiger BioPharmaceuticals’ stock price. This could potentially provide opportunities for short-term gains for those willing to take on the risk.
On the other hand, the potential for significant financial recovery through the lawsuit could provide a substantial upside for those who have incurred losses. However, this potential upside comes with the risk that the lawsuit may not be successful, or the recovery may be less than expected.
Conclusion
In conclusion, the class action lawsuit filed by the Schall Law Firm against Eiger BioPharmaceuticals presents a complex situation for investors. Those who have suffered significant losses are encouraged to reach out to the firm before the January 9, 2023 deadline to discuss their legal rights and options. Speculative investors may see potential opportunities amidst the uncertainty, but should be aware of the risks involved. As always, investors are advised to seek professional advice before making any decisions.